Scientists at the National Institute of Neurological Disorders and Stroke (NINDS) seek adults and children 12 years of age
or older with neuronopathic Gaucher disease who are currently being treated with enzyme replacement therapy for a study of
an investigational oral treatment for the disorder. It is hoped that this drug will be an effective treatment for the neurological
symptoms of this disease.

Individuals will be screened to determine eligibility. Initially, the duration of the study will be 12 months. Eligible persons
will be required to visit the clinic at regular 3-month intervals. The study will take place at the National Institutes of
Health (NIH) Clinical Center in Bethesda, MD. All study-related expenses will be paid by the NIH.